GlassScriptPhysician profile
Mark Dale Johnson
NPI 1184668659
$8,459.76
in general payments reported to CMS, 2019-2025
43 companies · $65.26 in 2025
The $65.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,660 · 2020: $1,455 · 2021: $1,785 · 2022: $1,476 · 2024: $17.75 · 2025: $65.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $1,698.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,050.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $449.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $432.58 | 2019-2022 | |
| Pfizer INC. | $406.99 | 2019-2022 | |
| Abbvie INC. | $398.13 | 2019-2022 | |
| Astellas Pharma US INC | $386.77 | 2019-2022 | |
| Novo Nordisk INC | $354.90 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $316.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $278.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $265.83 | 2019-2021 | |
| Amgen INC. | $245.65 | 2019-2022 | |
| Medicure Pharma INC. | $193.09 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $186.96 | 2019-2022 | |
| Amarin Pharma, INC. | $186.56 | 2019-2021 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.